<DOC>
	<DOCNO>NCT01587755</DOCNO>
	<brief_summary>A Topical Treatment Optimisation Programme ( TTOP ) develop sponsor together Patient Boards Expert Advisory Board overcome non-adherence problem .</brief_summary>
	<brief_title>Optimising Outpatient Care Mild Moderate Psoriasis ( PSO-TOP )</brief_title>
	<detailed_description>A Topical Treatment Optimisation Programme ( TTOP ) develop sponsor together Patient Boards Expert Advisory Board . This tool create address patient ' non-adherence topical therapy result underperformance treatment control psoriatic disease . The study address effect relationship patient health care professional , one important factor affect treatment adherence therapeutic efficacy . The TTOP compare standardise regular care ( call 'non-TTOP ' ) . It intend clinically show importance optimise contact patient health care professional .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female patient age least 18 year Mild moderate active plaque psoriasis PGA ≥ 2 7point scale Langley Ellis Body Surface Area ( BSA ) ≤ 10 % Topical psoriasis treatment coal tar preparation , tazarotene , steroid , vitamin D analogue , combination steroids vitamin D analogue ( except gel combination product contain 50 microgram calcipotriol/0.5mg betamethasone/g ) dithranol combination preparation last 8 week prior Visit 1 ( week 0 ) Written inform consent participate study give prior study related procedure Severe renal insufficiency Severe hepatic disorder Known hyper calcaemia Erythrodermic , exfoliative , pustular guttate psoriasis Facial genital psoriasis Fulfilment least one contraindication accord Summary Product Characteristics Daivobet®/Dovobet® Gel Pregnant and/or breastfeed woman Hypersensitivity active substance excipients Suspected noncompliance clinical study procedure Current participation another clinical study Systemic treatment biological therapy , whether market , possible effect psoriasis vulgaris within follow time period prior Visit 1 ( week 0 ) : etanercept within 4 week prior Visit 1 ( week 0 ) adalimumab , alefacept , infliximab within 2 month prior Visit 1 ( week 0 ) ustekinumab within 4 month prior Visit 1 ( week 0 ) experimental product within 4 weeks/5 halflives ( whichever longer ) prior Visit 1 ( week 0 ) Phototherapy within follow time period prior Visit 1 ( week 0 ) : PUVA within 4 week prior Visit 1 ( week 0 ) UVB within 2 week prior Visit 1 ( week 0 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>